Gemcitabine-Ebewe 1 g

Gemcitabine 10 mg/mL — Concentrate for Solution for IV Infusion

Product Description

Gemcitabine-Ebewe 1 g contains gemcitabine hydrochloride, a pyrimidine nucleoside analogue and antimetabolite chemotherapy agent. Gemcitabine interferes with DNA synthesis, thereby inhibiting the growth and survival of rapidly dividing cancer cells. It may be administered alone or in combination with other anticancer medicines, depending on the malignancy and treatment protocol.

Strength: 1,000 mg gemcitabine
Concentration: 10 mg/mL
Dosage form: Concentrate for solution for intravenous infusion
Route: Intravenous infusion after appropriate preparation/dilution
Class: Antimetabolite / nucleoside analogue cytotoxic chemotherapy

Mechanism of Action

Gemcitabine enters cells and is converted intracellularly into the active metabolites difluorodeoxycytidine diphosphate (dFdCDP) and difluorodeoxycytidine triphosphate (dFdCTP).

• dFdCDP inhibits ribonucleotide reductase, reducing the availability of deoxynucleotides required for DNA synthesis.
• dFdCTP is incorporated into DNA, resulting in inhibition of DNA-chain elongation and termination.
• These mechanisms interfere with DNA replication and can ultimately lead to cell-cycle arrest and apoptosis.

Indications & Clinical Uses

Gemcitabine is used as monotherapy or in combination with other anticancer medicines for several malignancies. Depending on the applicable regulatory approval and treatment protocol, established uses include:

Pancreatic Cancer

• Treatment of locally advanced or metastatic pancreatic adenocarcinoma. Gemcitabine may be used as a single agent or as part of combination treatment.

Bladder / Urothelial Cancer

• Used in combination with cisplatin for locally advanced or metastatic bladder cancer.

Non-Small Cell Lung Cancer (NSCLC)

• Used, particularly in combination with cisplatin, for locally advanced or metastatic NSCLC. Gemcitabine monotherapy may be considered in selected patients.

Ovarian Cancer

• Used in combination with carboplatin for advanced epithelial ovarian cancer that has relapsed after an appropriate interval following platinum-based treatment.

Breast Cancer

• Used with paclitaxel for unresectable, locally recurrent, or metastatic breast cancer following prior chemotherapy, subject to the applicable treatment criteria.

Gemcitabine is also used in other oncology protocols, including combinations for certain biliary tract and cervical cancers, according to specific clinical protocols and local approvals.

Administration & Dosing

Gemcitabine should be prescribed and administered by a physician experienced in the use of cytotoxic anticancer chemotherapy. It is administered by intravenous infusion, commonly over approximately 30 minutes.

The dose is individualized according to the cancer type, treatment regimen, body-surface area, blood counts, organ function, previous treatment, and treatment-related toxicity.

Examples of commonly used regimens include:

• Bladder cancer: 1,000 mg/m² on Days 1, 8 and 15 of a 28-day cycle, in combination with cisplatin.
• Ovarian cancer: commonly 1,000 mg/m² on Days 1 and 8 of a 21-day cycle with carboplatin.
• Breast cancer: commonly 1,250 mg/m² on Days 1 and 8 of a 21-day cycle with paclitaxel.
• NSCLC: commonly 1,000 mg/m² on Days 1, 8 and 15 of a 28-day cycle, or 1,250 mg/m² on Days 1 and 8 of a 21-day cycle.
• Pancreatic cancer: commonly 1,000 mg/m² once weekly for 7 weeks followed by a 1-week rest, then once weekly for 3 weeks of each subsequent 28-day cycle.

These are examples of established regimens and are not instructions for self-administration. The treating oncologist determines the appropriate regimen and any dose modifications.

Monitoring During Treatment

Because gemcitabine can affect blood-cell production and organ function, medical monitoring generally includes:

• Complete blood count (CBC)
• Neutrophil and platelet counts
• Hemoglobin
• Liver-function tests
• Renal function
• Clinical assessment for infection
• Assessment for treatment-related pulmonary, gastrointestinal, or other toxicity

Treatment may be delayed or the dose modified depending on laboratory findings and toxicity.

Important Warnings & Precautions

Myelosuppression
Gemcitabine can cause neutropenia, thrombocytopenia, and anemia. Severe bone-marrow suppression can increase the risk of infection, bleeding, and other complications.

Infections
Patients may be more susceptible to infections, particularly when significant neutropenia occurs. Fever or other signs of infection should receive prompt medical attention.

Hepatic toxicity
Gemcitabine may cause elevations in liver enzymes and, rarely, serious hepatic toxicity. Patients with pre-existing liver disease require appropriate clinical assessment and monitoring.

Renal toxicity
Serious renal complications, including hemolytic uremic syndrome (HUS), have been reported rarely. Renal function and relevant hematologic parameters should be monitored when clinically indicated.

Pulmonary toxicity
Serious pulmonary reactions, including interstitial pneumonitis and pulmonary edema, have been reported. New or worsening shortness of breath, cough, or other respiratory symptoms should be promptly evaluated.

Schedule-dependent toxicity
Administration for longer than the recommended infusion duration or more frequent dosing can increase toxicity. Gemcitabine should therefore be administered according to the established treatment protocol.

Common Adverse Effects

Depending on the indication and combination regimen, adverse effects may include:

• Nausea and vomiting
• Fatigue
• Fever
• Rash
• Headache
• Flu-like symptoms
• Peripheral edema
• Diarrhea or constipation
• Elevated liver enzymes
• Neutropenia
• Thrombocytopenia
• Anemia
• Increased susceptibility to infections

The overall adverse-effect profile can be influenced by other chemotherapy medicines administered alongside gemcitabine.

Preparation & Handling

Gemcitabine is a cytotoxic antineoplastic medicine. Preparation and administration should be performed by appropriately trained healthcare professionals using established procedures for handling hazardous/cytotoxic medicines.

The product should be prepared and diluted according to the current Gemcitabine-Ebewe product information, including requirements for compatible diluent, aseptic technique, infusion volume, stability, and administration.

Storage

Store Gemcitabine-Ebewe according to the manufacturer's current approved product information for the specific presentation.

Prepared infusion solutions should be handled, stored, and used within the stability period specified by the manufacturer and institutional chemotherapy procedures.

Patient Information

Patients should promptly contact their healthcare team if they experience:

• Fever, chills, or other signs of infection
• Unusual bleeding or bruising
• Severe weakness or fatigue
• Difficulty breathing or a new/worsening cough
• Significant swelling
• Reduced urine output
• Severe or persistent vomiting/diarrhea
• Yellowing of the skin or eyes
• Severe headache, confusion, seizures, or visual disturbances

Patients should inform their oncology team about all prescription medicines, OTC medicines, supplements, previous chemotherapy or radiotherapy, liver or kidney disease, and pregnancy or plans for pregnancy.

Patient / Medical Disclaimer

This information is provided for educational purposes only and is not intended to replace the advice of a qualified oncologist, hematologist, pharmacist, or other healthcare professional. Gemcitabine-Ebewe is a prescription cytotoxic chemotherapy medicine that must be prescribed, prepared, and administered by appropriately trained healthcare professionals. The dose and treatment schedule depend on the type and stage of cancer, treatment protocol, blood counts, kidney and liver function, previous treatments, and individual patient factors. Do not use, discontinue, or modify treatment without medical supervision. Always consult the current official product information and the treating oncology team before administration.

References

• National Cancer Institute (NCI) — Gemcitabine Hydrochloride.
• NCI Drug Dictionary — Gemcitabine Hydrochloride.
• U.S. FDA — Gemcitabine Injection Prescribing Information.
• Electronic Medicines Compendium — Gemcitabine 38 mg/mL SmPC.
• Electronic Medicines Compendium — Gemcitabine 10 mg/mL.

Note: The exact Gemcitabine-Ebewe 1 g presentation and concentration should be checked against the locally approved manufacturer leaflet before publication, particularly for excipients, dilution instructions, storage conditions, and shelf life.